CF
PTGX icon

Corebridge Financial’s Protagonist Therapeutics PTGX Stock Holding History

Corebridge Financial’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-31,020
Closed -$1.5M – 2112
2025
Q1 		$1.5M Sell
31,020
-135
-0.4% -$5.66K 0.01% 1095
2024
Q4 		$1.2M Sell
31,155
-2,407
-7% -$105K 0.01% 1244
2024
Q3 		$1.51M Buy
33,562
+2,122
+7% +$85.7K 0.01% 1169
2024
Q2 		$1.09M Buy
+31,440
New +$921K 0.01% 1287

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Corebridge Financial's PTGX Position: Q2 2025 in Review

Corebridge Financial sold out of Protagonist Therapeutics (PTGX) in Q2 2025, closing a stake of 31,020 shares — an estimated $1.5M sold.

Corebridge Financial first reported a position in PTGX in Q2 2024 and held it in 4 quarters. The position peaked at $1.51M in Q3 2024. 272 funds tracked by Wall St. Rank hold PTGX as of Q2 2025.

  • Corebridge Financial reported no remaining Protagonist Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 31,020 Protagonist Therapeutics shares in Q2 2025, an estimated $1.5M.
  • Corebridge Financial first reported a position in Protagonist Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Protagonist Therapeutics position peaked at $1.51M in Q3 2024.
  • 272 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.